In the context of MMRd CRC tumors, we observed complete responses of 20%, 50% and 10% for anti-PD1/TREM2, anti-PD1/LAG3/TREM2 and anti-PD1/IFITM respectively (Figure 4 D, Extended Figure 15 D). This evidence concerns the gene TREM2 and colorectal carcinoma.